Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 3.1.3.46 - fructose-2,6-bisphosphate 2-phosphatase and Organism(s) Homo sapiens

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Abortion, Habitual
Acceleration of the glycolytic flux by steroid receptor coactivator-2 is essential for endometrial decidualization.
Acidosis
Characterization of human fructose-1,6-bisphosphatase in control and deficient tissues.
Fructose 1,6-bisphosphatase deficiency: enzyme and mutation analysis performed on calcitriol-stimulated monocytes with a note on long-term prognosis.
Fructose-1,6-bisphosphatase deficiency as a cause of recurrent hypoglycemia and metabolic acidosis: Clinical and molecular findings in Malaysian patients.
Fructose-1,6-bisphosphatase deficiency presented with complex febrile convulsion.
Intravenous glycerol therapy should not be used in patients with unrecognized fructose-1,6-bisphosphatase deficiency.
Acidosis, Lactic
Fructose-1,6-bisphosphatase deficiency with confirmed molecular diagnosis. An important cause of hypoglycemia in children.
Novel compound heterozygous mutations in the fructose-1,6-bisphosphatase gene cause hypoglycemia and lactic acidosis.
Pitfall in the Diagnosis of Fructose-1,6-Bisphosphatase Deficiency: Difficulty in Detecting Glycerol-3-Phosphate with Solvent Extraction in Urinary GC/MS Analysis.
Acute Kidney Injury
LncRNA XIST serves as a ceRNA to regulate the expression of ASF1A, BRWD1M, and PFKFB2 in kidney transplant acute kidney injury via sponging hsa-miR-212-3p and hsa-miR-122-5p.
Acute Lung Injury
Ablation of endothelial Pfkfb3 protects mice from acute lung injury in LPS-induced endotoxemia.
Blockage of glycolysis by targeting PFKFB3 alleviates sepsis-related acute lung injury via suppressing inflammation and apoptosis of alveolar epithelial cells.
Adenocarcinoma
Dynamic ROS Control by TIGAR Regulates the Initiation and Progression of Pancreatic Cancer.
Dynamic ROS Regulation by TIGAR: Balancing Anti-cancer and Pro-metastasis Effects.
Expression of PFKFB3 and Ki67 in lung adenocarcinomas and targeting PFKFB3 as a therapeutic strategy.
Expression of TIGAR and its correlation with clinicopathology, prognosis, and 18F-FDG PET/CT parameters in patients with resectable pancreatic ductal adenocarcinoma.
Interleukin-6 stimulates aerobic glycolysis by regulating PFKFB3 at early stage of colorectal cancer.
PFKFB2 regulates glycolysis and proliferation in pancreatic cancer cells.
Studying Antitumor Effects of Sirna Gene Silencing of some Metabolic Genes in Pancreatic Ductal Adenocarcinoma.
The Role of CD44 in Glucose Metabolism in Prostatic Small Cell Neuroendocrine Carcinoma.
Adenocarcinoma of Lung
Expression of PFKFB3 and Ki67 in lung adenocarcinomas and targeting PFKFB3 as a therapeutic strategy.
High expression of synthesis of cytochrome c oxidase 2 and TP53-induced glycolysis and apoptosis regulator can predict poor prognosis in human lung adenocarcinoma.
PFKFB4 promotes lung adenocarcinoma progression via phosphorylating and activating transcriptional coactivator SRC-2.
Plasminogen/plasmin affects expression of glycolysis regulator TIGAR and induces autophagy in lung adenocarcinoma A549 cells.
Structure-based design of small-molecule ligands of phosphofructokinase-2 activating or inhibiting glycolysis.
Adenoma
Dynamic ROS Control by TIGAR Regulates the Initiation and Progression of Pancreatic Cancer.
Interleukin-6 stimulates aerobic glycolysis by regulating PFKFB3 at early stage of colorectal cancer.
TIGAR is required for efficient intestinal regeneration and tumorigenesis.
Alzheimer Disease
NF-?B-Induced Upregulation of miR-146a-5p Promoted Hippocampal Neuronal Oxidative Stress and Pyroptosis via TIGAR in a Model of Alzheimer's Disease.
Astrocytoma
6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB3) is up-regulated in high-grade astrocytomas.
Prognostic Value of PFKFB3 to PFKFB4 mRNA Ratio in Patients With Primary Glioblastoma (IDH-Wildtype).
The PFKFB3 splice variant UBI2K4 is down-regulated in high-grade astrocytomas and impedes the growth of U87 glioblastoma cells.
Atherosclerosis
Inhibition of PFKFB3 Hampers the Progression of Atherosclerosis and Promotes Plaque Stability.
Partial Inhibition of the 6-Phosphofructo-2-Kinase/Fructose-2,6-Bisphosphatase-3 (PFKFB3) Enzyme in Myeloid Cells Does Not Affect Atherosclerosis.
TIGAR mitigates atherosclerosis by promoting cholesterol efflux from macrophages.
[18F]ZCDD083: A PFKFB3-Targeted PET Tracer for Atherosclerotic Plaque Imaging.
Autoimmune Diseases
First Genome-Wide Association Study of Latent Autoimmune Diabetes in Adults Reveals Novel Insights Linking Immune and Metabolic Diabetes.
Bacterial Infections
Signatures of selection reveal candidate genes involved in economic traits and cold acclimation in five Swedish cattle breeds.
Brain Edema
Intravenous glycerol therapy should not be used in patients with unrecognized fructose-1,6-bisphosphatase deficiency.
Brain Injuries
A TIGAR-regulated metabolic pathway is critical for protection of brain ischemia.
The E3 ubiquitin ligase TRIM31 is involved in cerebral ischemic injury by promoting degradation of TIGAR.
TIGAR alleviates ischemia/reperfusion-induced autophagy and ischemic brain injury.
TIGAR contributes to ischemic tolerance induced by cerebral preconditioning through scavenging of reactive oxygen species and inhibition of apoptosis.
Brain Ischemia
A TIGAR-regulated metabolic pathway is critical for protection of brain ischemia.
PFKFB3-mediated glycolysis is involved in reactive astrocyte proliferation after oxygen-glucose deprivation/reperfusion and is regulated by Cdh1.
The E3 ubiquitin ligase TRIM31 is involved in cerebral ischemic injury by promoting degradation of TIGAR.
Breast Neoplasms
6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase-2 Regulates TP53-Dependent Paclitaxel Sensitivity in Ovarian and Breast Cancers.
Aberrant methylation of human L- and M-fructose 1,6-bisphosphatase genes in cancer.
AMPK and PFKFB3 mediate glycolysis and survival in response to mitophagy during mitotic arrest.
CD44ICD promotes breast cancer stemness via PFKFB4-mediated glucose metabolism.
Downregulation of caveolin?1 upregulates the expression of growth factors and regulators in co?culture of fibroblasts with cancer cells.
Downregulation of TIGAR sensitizes the antitumor effect of physapubenolide through increasing intracellular ROS levels to trigger apoptosis and autophagosome formation in human breast carcinoma cells.
Estradiol Stimulates Glucose Metabolism via 6-Phosphofructo-2-kinase (PFKFB3).
High expression of metabolic enzyme PFKFB4 is associated with poor prognosis of operable breast cancer.
Inhibition of 6-phosphofructo-2-kinase (PFKFB3) suppresses glucose metabolism and the growth of HER2+ breast cancer.
Mechanisms of regulation of PFKFB expression in pancreatic and gastric cancer cells.
Metabolic enzyme PFKFB4 activates transcriptional coactivator SRC-3 to drive breast cancer.
Non-canonical roles of PFKFB3 in regulation of cell cycle through binding to CDK4.
Overexpression of miR-206 suppresses glycolysis, proliferation and migration in breast cancer cells via PFKFB3 targeting.
PELP1/SRC-3-dependent regulation of metabolic PFKFB kinases drives therapy resistant ER+ breast cancer.
PFKFB3 is involved in breast cancer proliferation, migration, invasion and angiogenesis.
PFKFB3 potentially contributes to paclitaxel resistance in breast cancer cells through TLR4 activation by stimulating lactate production.
PFKFB4 Promotes Breast Cancer Metastasis via Induction of Hyaluronan Production in a p38-Dependent Manner.
Positive regulation of PFKFB3 by PIM2 promotes glycolysis and paclitaxel resistance in breast cancer.
Progestins activate 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3) in breast cancer cells.
Regulatory role of p53 in cancer metabolism via SCO2 and TIGAR in human breast cancer.
Sonic hedgehog stimulates glycolysis and proliferation of breast cancer cells: Modulation of PFKFB3 activation.
Structure-based design of small-molecule ligands of phosphofructokinase-2 activating or inhibiting glycolysis.
TP53-inducible Glycolysis and Apoptosis Regulator (TIGAR) Metabolically Reprograms Carcinoma and Stromal Cells in Breast Cancer.
Carcinogenesis
6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB3) is up-regulated in high-grade astrocytomas.
c-Src Promotes Tumorigenesis and Tumor Progression by Activating PFKFB3.
Expression of PFKFB3 and Ki67 in lung adenocarcinomas and targeting PFKFB3 as a therapeutic strategy.
Identification of the TP53-induced glycolysis and apoptosis regulator in various stages of colorectal cancer patients.
miR-885-5p plays an accomplice role in liver cancer by instigating TIGAR expression via targeting its promoter.
Oncogenic role of the TP53-induced glycolysis and apoptosis regulator in nasopharyngeal carcinoma through NF-?B pathway modulation.
p38? MAPK Is Essential for Aerobic Glycolysis and Pancreatic Tumorigenesis.
PFKFB3 Control of Cancer Growth by Responding to Circadian Clock Outputs.
PFKFB4 negatively regulated the expression of histone acetyltransferase GCN5 to mediate the tumorigenesis of thyroid cancer.
PFKFB4 Overexpression Facilitates Proliferation by Promoting the G1/S Transition and Is Associated with a Poor Prognosis in Triple-Negative Breast Cancer.
Prognostic Values of TIGAR Expression and 18F-FDG PET/CT in Clear Cell Renal Cell Carcinoma.
Role of PFKFB3 and CD163 in Oral Squamous Cell Carcinoma Angiogenesis.
Role of PFKFB3 and PFKFB4 in Cancer: Genetic Basis, Impact on Disease Development/Progression, and Potential as Therapeutic Targets.
Roles of PFKFB3 in cancer.
TIGAR is required for efficient intestinal regeneration and tumorigenesis.
TIGAR Promotes Tumorigenesis and Protects Tumor Cells From Oxidative and Metabolic Stresses in Gastric Cancer.
TIGAR, TIGAR, burning bright.
Carcinoma
6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene family overexpression in human lung tumor.
Blockage of glycolysis by targeting PFKFB3 suppresses tumor growth and metastasis in head and neck squamous cell carcinoma.
Hypoxia-induced hsa-miR-101 promotes glycolysis by targeting TIGAR mRNA in clear cell renal cell carcinoma.
Increased expression of PFKFB3 in oral squamous cell carcinoma and its association with lymphangiogenesis.
Metabolic remodeling by TIGAR overexpression is a therapeutic target in esophageal squamous-cell carcinoma.
microRNA-144 inhibits cell proliferation and invasion by directly targeting TIGAR in esophageal carcinoma.
PFKFB4 as a prognostic marker in non-muscle-invasive bladder cancer.
Phosphorylation of the 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase/PFKFB3 family of glycolytic regulators in human cancer.
Prognostic Values of TIGAR Expression and 18F-FDG PET/CT in Clear Cell Renal Cell Carcinoma.
Role of PFKFB3 and CD163 in Oral Squamous Cell Carcinoma Angiogenesis.
The diverse role of TIGAR in cellular homeostasis and cancer.
The role of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 in esophageal squamous cell carcinoma.
The Role of CD44 in Glucose Metabolism in Prostatic Small Cell Neuroendocrine Carcinoma.
TP53-inducible Glycolysis and Apoptosis Regulator (TIGAR) Metabolically Reprograms Carcinoma and Stromal Cells in Breast Cancer.
Carcinoma, Hepatocellular
Adenovirus-mediated overexpression of liver 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase in gluconeogenic rat hepatoma cells. Paradoxical effect on Fru-2,6-P2 levels.
By inhibiting PFKFB3, aspirin overcomes sorafenib resistance in hepatocellular carcinoma.
Characterization of the human liver fructose-1,6-bisphosphatase gene promoter.
Cloning and expression in Escherichia coli of a rat hepatoma cell cDNA coding for 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase.
Coordinated Expression of 6-Phosphofructo-2-kinase/Fructose-2,6-bisphosphatase 4 and Heme Oxygenase 2: Evidence for a Regulatory Link between Glycolysis and Heme Catabolism.
Expression and hypoxia-responsiveness of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 in mammary gland malignant cell lines.
Expression of the liver 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase mRNA in FAO-1 cells.
Fructose 2,6-bisphosphate and the control of glycolysis by growth factors, tumor promoters and oncogenes.
Hormonal control of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene expression in rat hepatoma cells.
Inhibition of glycolytic activator PFKFB3 suppresses tumor growth and induces tumor vessel normalization in hepatocellular carcinoma.
Insulin inhibits glucocorticoid-induced stimulation of liver 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene transcription.
Knockdown of TIGAR by RNA interference induces apoptosis and autophagy in HepG2 hepatocellular carcinoma cells.
Long noncoding RNA FIRRE contributes to the proliferation and glycolysis of hepatocellular carcinoma cells by enhancing PFKFB4 expression.
MACC1 expression correlates with PFKFB2 and survival in hepatocellular carcinoma.
PFKFB3 blockade inhibits hepatocellular carcinoma growth by impairing DNA repair through AKT.
PFKFB3/HIF-1? feedback loop modulates sorafenib resistance in hepatocellular carcinoma cells.
Phosphorylation of PPAR? at Ser84 promotes glycolysis and cell proliferation in hepatocellular carcinoma by targeting PFKFB4.
Rat hepatoma (HTC) cell 6-phosphofructo-2-kinase differs from that in liver and can be separated from fructose-2,6-bisphosphatase.
Two p53-related metabolic regulators, TIGAR and SCO2, contribute to oroxylin A-mediated glucose metabolism in human hepatoma HepG2 cells.
Carcinoma, Intraductal, Noninfiltrating
Relocation of phosphofructokinases within epithelial cells is a novel event preceding breast cancer recurrence that accurately predicts patient outcomes.
Carcinoma, Non-Small-Cell Lung
Increased 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 activity in response to EGFR signaling contributes to non-small cell lung cancer cell survival.
Liposomes co-Loaded with 6-Phosphofructo-2-Kinase/Fructose-2, 6-Biphosphatase 3 (PFKFB3) shRNA Plasmid and Docetaxel for the Treatment of non-small Cell Lung Cancer.
The Effect of TIGAR Knockdown on Apoptotic and Epithelial-Mesenchymal Markers Expression in Doxorubicin-Resistant Non-Small Cell Lung Cancer A549 Cell Lines.
TIGAR is correlated with maximal standardized uptake value on FDG-PET and survival in non-small cell lung cancer.
Carcinoma, Renal Cell
Hypoxia-induced hsa-miR-101 promotes glycolysis by targeting TIGAR mRNA in clear cell renal cell carcinoma.
Prognostic Values of TIGAR Expression and 18F-FDG PET/CT in Clear Cell Renal Cell Carcinoma.
Carcinoma, Small Cell
The Role of CD44 in Glucose Metabolism in Prostatic Small Cell Neuroendocrine Carcinoma.
Carcinoma, Squamous Cell
Blockage of glycolysis by targeting PFKFB3 suppresses tumor growth and metastasis in head and neck squamous cell carcinoma.
Cardiomegaly
Regulatory role of TIGAR on endothelial metabolism and angiogenesis.
Cardiovascular Diseases
TIGAR mitigates atherosclerosis by promoting cholesterol efflux from macrophages.
Choroidal Neovascularization
YAP promotes ocular neovascularization by modifying PFKFB3-driven endothelial glycolysis.
Clonorchiasis
Biochemical characterization and functional analysis of fructose-1,6-bisphosphatase from Clonorchis sinensis.
Colitis, Ulcerative
TIGAR is required for efficient intestinal regeneration and tumorigenesis.
Colonic Neoplasms
Insulin induces PFKFB3 gene expression in HT29 human colon adenocarcinoma cells.
Mechanisms of regulation of PFKFB expression in pancreatic and gastric cancer cells.
PFKFB3 Inhibition Attenuates Oxaliplatin-Induced Autophagy and Enhances Its Cytotoxicity in Colon Cancer Cells.
Structure-based design of small-molecule ligands of phosphofructokinase-2 activating or inhibiting glycolysis.
Systematic Analysis of Gene Expression Alterations and Clinical Outcomes for Long-Chain Acyl-Coenzyme A Synthetase Family in Cancer.
Colorectal Neoplasms
Effects of the Novel PFKFB3 Inhibitor KAN0438757 on Colorectal Cancer Cells and Its Systemic Toxicity Evaluation In Vivo.
Identification of the TP53-induced glycolysis and apoptosis regulator in various stages of colorectal cancer patients.
Interleukin-6 stimulates aerobic glycolysis by regulating PFKFB3 at early stage of colorectal cancer.
Mir-488 alleviates chemoresistance and glycolysis of colorectal cancer by targeting PFKFB3.
Necroptosis pathway blockage attenuates PFKFB3 inhibitor-induced cell viability loss and genome instability in colorectal cancer cells.
PFKFB3 Inhibition Attenuates Oxaliplatin-Induced Autophagy and Enhances Its Cytotoxicity in Colon Cancer Cells.
Targeting MUC1-C inhibits the AKT-S6K1-elF4A pathway regulating TIGAR translation in colorectal cancer.
TIGAR knockdown enhanced the anticancer effect of aescin via regulating autophagy and apoptosis in colorectal cancer cells.
COVID-19
Meta-analysis of transcriptome datasets: An alternative method to study IL-6 regulation in coronavirus disease 2019.
Dehydration
Inhibition of photosynthesis and energy dissipation induced by water and high light stresses in rice.
Phosphoproteomic Analysis of X enopus laevis Reveals Expression and Phosphorylation of Hypoxia-Inducible PFKFB3 during Dehydration.
Dementia
TIGAR inclusion pathology is specific for Lewy body diseases.
Diabetes Mellitus
Cardiac Insulin Signaling Regulates Glycolysis Through Phosphofructokinase 2 Content and Activity.
Discovery of N-Arylsulfonyl-Indole-2-Carboxamide Derivatives as Potent, Selective, and Orally Bioavailable Fructose-1,6-Bisphosphatase Inhibitors-Design, Synthesis, In Vivo Glucose Lowering Effects, and X-ray Crystal Complex Analysis.
Insulin resistance: an additional risk factor in the pathogenesis of cardiovascular disease in type 2 diabetes.
Low glucose enhanced metformin's inhibitory effect on pancreatic cancer cells by suppressing glycolysis and inducing energy stress via up-regulation of miR-210-5p.
[Changes in the level of fructose-2,6-biphosphate in peripheral blood lymphocytes in patients with diabetes mellitus]
Diabetes Mellitus, Type 1
Activation of the HIF1?/PFKFB3 stress response pathway in beta cells in type 1 diabetes.
Cardiac Insulin Signaling Regulates Glycolysis Through Phosphofructokinase 2 Content and Activity.
First Genome-Wide Association Study of Latent Autoimmune Diabetes in Adults Reveals Novel Insights Linking Immune and Metabolic Diabetes.
Mononuclear and polymorphonuclear leukocytes show increased fructose-1,6-bisphosphatase activity in patients with type 1 diabetes mellitus.
Diabetes Mellitus, Type 2
A cis-eQTL in PFKFB2 is associated with diabetic nephropathy, adiposity and insulin secretion in American Indians.
Additive activation of glucokinase by the bifunctional enzyme 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase and the chemical activator LY2121260.
Discovery of N-Arylsulfonyl-Indole-2-Carboxamide Derivatives as Potent, Selective, and Orally Bioavailable Fructose-1,6-Bisphosphatase Inhibitors-Design, Synthesis, In Vivo Glucose Lowering Effects, and X-ray Crystal Complex Analysis.
First Genome-Wide Association Study of Latent Autoimmune Diabetes in Adults Reveals Novel Insights Linking Immune and Metabolic Diabetes.
Fructose-1,6-bisphosphatase inhibitors. 1. Purine phosphonic acids as novel AMP mimics.
Fructose-1,6-bisphosphatase Inhibitors. 2. Design, synthesis, and structure-activity relationship of a series of phosphonic acid containing benzimidazoles that function as 5'-adenosinemonophosphate (AMP) mimics.
Fructose-1,6-bisphosphatase overexpression in pancreatic beta-cells results in reduced insulin secretion: a new mechanism for fat-induced impairment of beta-cell function.
Increased glucose production in mice overexpressing human fructose-1,6-bisphosphatase in the liver.
Inhibition of fructose 1,6-bisphosphatase reduces excessive endogenous glucose production and attenuates hyperglycemia in zucker diabetic Fatty rats.
MB06322 (CS-917): A potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes.
Structure-guided design of AMP mimics that inhibit fructose-1,6-bisphosphatase with high affinity and specificity.
Diabetic Cardiomyopathies
Sirtuin 3 Alleviates Diabetic Cardiomyopathy by Regulating TIGAR and Cardiomyocyte Metabolism.
Diabetic Nephropathies
A cis-eQTL in PFKFB2 is associated with diabetic nephropathy, adiposity and insulin secretion in American Indians.
Diabetic Neuropathies
TIGAR Attenuates High Glucose-Induced Neuronal Apoptosis via an Autophagy Pathway.
Embolism
Interleukin-6 stimulates aerobic glycolysis by regulating PFKFB3 at early stage of colorectal cancer.
Endometrial Neoplasms
Inhibition of PFKFB3 induces cell death and synergistically enhances chemosensitivity in endometrial cancer.
Endometriosis
HSF1 promotes endometriosis development and glycolysis by up-regulating PFKFB3 expression.
Endotoxemia
Ablation of endothelial Pfkfb3 protects mice from acute lung injury in LPS-induced endotoxemia.
Epilepsy
miR-485 inhibits histone deacetylase HDAC5, HIF1? and PFKFB3 expression to alleviate epilepsy in cellular and rodent models.
TIGAR suppresses seizures induced by kainic acid through inhibiting oxidative stress and neuronal apoptosis.
Esophageal Neoplasms
microRNA-144 inhibits cell proliferation and invasion by directly targeting TIGAR in esophageal carcinoma.
Esophageal Squamous Cell Carcinoma
The role of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 in esophageal squamous cell carcinoma.
Fanconi Anemia
Genome-scale CRISPR knockout screen identifies TIGAR as a modifier of PARP inhibitor sensitivity.
PFKFB3 Inhibition Sensitizes DNA Crosslinking Chemotherapies by Suppressing Fanconi Anemia Repair.
fructose-2,6-bisphosphate 2-phosphatase deficiency
A potential role for muscle in glucose homeostasis: in vivo kinetic studies in glycogen storage disease type 1a and fructose-1,6-bisphosphatase deficiency.
Characterization of human fructose-1,6-bisphosphatase in control and deficient tissues.
Clinical and Molecular Characterization of Patients with Fructose 1,6-Bisphosphatase Deficiency.
Diagnosis of fructose-1,6-bisphosphatase deficiency using cultured lymphocyte fraction: a secure and noninvasive alternative to liver biopsy.
Disruption of endothelial Pfkfb3 ameliorates diet-induced murine insulin resistance.
Fructose 1,6-bisphosphatase deficiency: clinical, biochemical and genetic features in French patients.
Fructose 1,6-bisphosphatase deficiency: enzyme and mutation analysis performed on calcitriol-stimulated monocytes with a note on long-term prognosis.
Fructose-1,6-bisphosphatase deficiency as a cause of recurrent hypoglycemia and metabolic acidosis: Clinical and molecular findings in Malaysian patients.
Fructose-1,6-bisphosphatase deficiency caused by a novel homozygous Alu element insertion in the FBP1 gene and delayed diagnosis.
Fructose-1,6-bisphosphatase deficiency presented with complex febrile convulsion.
Fructose-1,6-bisphosphatase deficiency with confirmed molecular diagnosis. An important cause of hypoglycemia in children.
Fructose-1,6-Bisphosphatase Deficiency: A Case of a Successful Pregnancy by Closely Monitoring Metabolic Control.
Genetic analysis of fructose-1,6-bisphosphatase (FBPase) deficiency in nine consanguineous Pakistani families.
Genetic analysis of patients with fructose-1,6-bisphosphatase deficiency.
Identification of a response element for vitamin D3 and retinoic acid in the promoter region of the human fructose-1,6-bisphosphatase gene.
Identification of genetic mutations in Japanese patients with fructose-1,6-bisphosphatase deficiency.
International practices in the dietary management of fructose 1-6 biphosphatase deficiency.
Intravenous glycerol therapy should not be used in patients with unrecognized fructose-1,6-bisphosphatase deficiency.
Mice with a specific deficiency of Pfkfb3 in myeloid cells are protected from hypoxia-induced pulmonary hypertension.
Novel compound heterozygous mutations in the fructose-1,6-bisphosphatase gene cause hypoglycemia and lactic acidosis.
Novel Fructose-1,6-bisphosphatase Gene Mutation in Two Siblings.
Novel mutations in patients with fructose-1,6-bisphosphatase deficiency.
Phosphofructokinase deficiency impairs ATP generation, autophagy, and redox balance in rheumatoid arthritis T cells.
Pitfall in the Diagnosis of Fructose-1,6-Bisphosphatase Deficiency: Difficulty in Detecting Glycerol-3-Phosphate with Solvent Extraction in Urinary GC/MS Analysis.
Role of PFKFB3-driven glycolysis in vessel sprouting.
Status epilepticus due to fructose-1,6-bisphosphatase deficiency caused by FBP1 gene mutation.
Three successful pregnancies through dietary management of fructose-1,6-bisphosphatase deficiency.
TIGAR contributes to ischemic tolerance induced by cerebral preconditioning through scavenging of reactive oxygen species and inhibition of apoptosis.
TIGAR is required for efficient intestinal regeneration and tumorigenesis.
TIGAR mitigates atherosclerosis by promoting cholesterol efflux from macrophages.
TIGAR promotes neural stem cell differentiation through acetyl-CoA-mediated histone acetylation.
Two newly identified genomic mutations in a Japanese female patient with fructose-1,6-bisphosphatase (FBPase) deficiency.
Glioblastoma
6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB3) is up-regulated in high-grade astrocytomas.
Dual inhibition of PFKFB3 and VEGF normalizes tumor vasculature, reduces lactate production, and improves chemotherapy in glioblastoma: insights from protein expression profiling and MRI.
Functional diversity of PFKFB3 splice variants in glioblastomas.
LOH on 10p14-p15 targets the PFKFB3 gene locus in human glioblastomas.
Prognostic Value of PFKFB3 to PFKFB4 mRNA Ratio in Patients With Primary Glioblastoma (IDH-Wildtype).
RNAi screening in glioma stem-like cells identifies PFKFB4 as a key molecule important for cancer cell survival.
TGF-?1 targets Smad, p38 MAPK, and PI3K/Akt signaling pathways to induce PFKFB3 gene expression and glycolysis in glioblastoma cells.
The PFKFB3 splice variant UBI2K4 is down-regulated in high-grade astrocytomas and impedes the growth of U87 glioblastoma cells.
TIGAR promotes growth, survival and metastasis through oxidation resistance and AKT activation in glioblastoma.
TP53 induced glycolysis and apoptosis regulator (TIGAR) knockdown results in radiosensitization of glioma cells.
Tp53-induced glycolysis and apoptosis regulator (TIGAR) protects glioma cells from starvation-induced cell death by upregulating respiration and improving cellular redox homeostasis.
Glioma
ATM-NF?B axis-driven TIGAR regulates sensitivity of glioma cells to radiomimetics in the presence of TNF?.
E2F2 drives glioma progression via PI3K/AKT in a PFKFB4-dependent manner.
IDH1-R132H mutation radiosensitizes U87MG glioma cells via epigenetic downregulation of TIGAR.
Knockdown of the TP53-Induced Glycolysis and Apoptosis Regulator (TIGAR) Sensitizes Glioma Cells to Hypoxia, Irradiation and Temozolomide.
Long non-coding RNA UCA1/miR-182/PFKFB2 axis modulates glioblastoma-associated stromal cells-mediated glycolysis and invasion of glioma cells.
Radiosensitization of glioma cells by TP53-induced glycolysis and apoptosis regulator knockdown is dependent on thioredoxin-1 nuclear translocation.
RNAi screening in glioma stem-like cells identifies PFKFB4 as a key molecule important for cancer cell survival.
TGF-?-induced hCG-? regulates redox homeostasis in glioma cells.
TGF-?1 targets Smad, p38 MAPK, and PI3K/Akt signaling pathways to induce PFKFB3 gene expression and glycolysis in glioblastoma cells.
TIGAR knockdown radiosensitizes TrxR1-overexpressing glioma in vitro and in vivo via inhibiting Trx1 nuclear transport.
TIGAR promotes growth, survival and metastasis through oxidation resistance and AKT activation in glioblastoma.
Tp53-induced glycolysis and apoptosis regulator (TIGAR) protects glioma cells from starvation-induced cell death by upregulating respiration and improving cellular redox homeostasis.
[EXPRESSION OF PFKFB, HK2, NAMPT, TSPAN13 AND HSPB8 GENES IN PEDIATRIC GLIOMA].
Glucose Intolerance
[EXPRESSION OF GENES, WHICH CONTROL GLUCOSE METABOLISM, IN BLOOD CELLS OF THE OBESE BOYS WITH INSULIN RESISTANCE].
Heart Diseases
Amylin deposition activates HIF1? and 6-phosphofructo-2-kinase/fructose-2, 6-biphosphatase 3 (PFKFB3) signaling in failing hearts of non-human primates.
Heart Failure
Ablation of cardiac TIGAR preserves myocardial energetics and cardiac function in the pressure overload heart failure model.
Amylin deposition activates HIF1? and 6-phosphofructo-2-kinase/fructose-2, 6-biphosphatase 3 (PFKFB3) signaling in failing hearts of non-human primates.
Hyperglycemia
CS-917, a fructose 1,6-bisphosphatase inhibitor, improves postprandial hyperglycemia after meal loading in non-obese type 2 diabetic Goto-Kakizaki rats.
Nuclear accumulation of fructose 1,6-bisphosphatase is impaired in diabetic rat liver.
Hypertension
Involvement of PFKFB3 in Pulmonary Arterial Hypertension Pathogenesis. Is It All about Glycolysis?
PFKFB3 in Smooth Muscle Promotes Vascular Remodeling in Pulmonary Arterial Hypertension.
Hypertension, Pulmonary
Mice with a specific deficiency of Pfkfb3 in myeloid cells are protected from hypoxia-induced pulmonary hypertension.
TIGAR reduces smooth muscle cell autophagy to prevent pulmonary hypertension.
Hypoglycemia
Characterization of recombinant fructose-1,6-bisphosphatase gene mutations: evidence of inhibition/activation of FBPase protein by gene mutation.
Fructose 1,6-bisphosphatase deficiency: enzyme and mutation analysis performed on calcitriol-stimulated monocytes with a note on long-term prognosis.
Fructose-1,6-bisphosphatase deficiency as a cause of recurrent hypoglycemia and metabolic acidosis: Clinical and molecular findings in Malaysian patients.
Fructose-1,6-bisphosphatase deficiency presented with complex febrile convulsion.
Fructose-1,6-bisphosphatase deficiency with confirmed molecular diagnosis. An important cause of hypoglycemia in children.
Fructose-1,6-Bisphosphatase Deficiency: A Case of a Successful Pregnancy by Closely Monitoring Metabolic Control.
Intravenous glycerol therapy should not be used in patients with unrecognized fructose-1,6-bisphosphatase deficiency.
JAK2 mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms.
Muscle fructose-2,6-bisphosphate and glucose-1,6-bisphosphate during insulin-induced hypoglycemia.
Novel compound heterozygous mutations in the fructose-1,6-bisphosphatase gene cause hypoglycemia and lactic acidosis.
Pitfall in the Diagnosis of Fructose-1,6-Bisphosphatase Deficiency: Difficulty in Detecting Glycerol-3-Phosphate with Solvent Extraction in Urinary GC/MS Analysis.
Role of epinephrine during insulin-induced hypoglycemia in fasted rats.
Hypotension
Alterations in hepatic 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase and glucose-6-phosphatase gene expression after hemorrhagic hypotension and resuscitation.
Idiopathic Pulmonary Fibrosis
Glycolytic Reprogramming in Myofibroblast Differentiation and Lung Fibrosis.
Infections
Fructose 1,6-bisphosphatase deficiency: enzyme and mutation analysis performed on calcitriol-stimulated monocytes with a note on long-term prognosis.
Genetic Variation in PFKFB3 Impairs Antifungal Immunometabolic Responses and Predisposes to Invasive Pulmonary Aspergillosis.
Inhibition of eNOS by L-NAME resulting in rat hind limb developmental defects through PFKFB3 mediated angiogenetic pathway.
Infertility
Acceleration of the glycolytic flux by steroid receptor coactivator-2 is essential for endometrial decidualization.
Insulin Resistance
Activation of p53 enhances apoptosis and insulin resistance in a rat model of alcoholic liver disease.
Adipocyte inducible 6-phosphofructo-2-kinase suppresses adipose tissue inflammation and promotes macrophage anti-inflammatory activation.
Adipose tissue inflammation and systemic insulin resistance in mice with diet-induced obesity is possibly associated with disruption of PFKFB3 in hematopoietic cells.
Cardiac expression of kinase-deficient 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase inhibits glycolysis, promotes hypertrophy, impairs myocyte function, and reduces insulin sensitivity.
Disruption of endothelial Pfkfb3 ameliorates diet-induced murine insulin resistance.
Epigenetic regulation of diabetogenic adipose morphology.
Exercise training attenuates oxidative stress and decreases p53 protein content in skeletal muscle of type 2 diabetic Goto-Kakizaki rats.
Fructose-1, 6-bisphosphatase inhibitors for reducing excessive endogenous glucose production in type 2 diabetes.
Jejunal gluconeogenesis associated with insulin resistance level and its evolution after Roux-en-Y gastric bypass.
Potential effect of exercise in ameliorating insulin resistance at transcriptome level.
Regulation of hepatic gluconeogenesis and glycogenolysis by phosphorylated glycerol and glycolytic intermediates in diabetic and control Chinese hamsters.
[EXPRESSION OF GENES, WHICH CONTROL GLUCOSE METABOLISM, IN BLOOD CELLS OF THE OBESE BOYS WITH INSULIN RESISTANCE].
Intervertebral Disc Degeneration
TIGAR impedes compression-induced intervertebral disc degeneration by suppressing nucleus pulposus cell apoptosis and autophagy.
TIGAR mediates the inhibitory role of hypoxia on ROS production and apoptosis in rat nucleus pulposus cells.
Intestinal Neoplasms
TIGAR is required for efficient intestinal regeneration and tumorigenesis.
Invasive Pulmonary Aspergillosis
Genetic Variation in PFKFB3 Impairs Antifungal Immunometabolic Responses and Predisposes to Invasive Pulmonary Aspergillosis.
Ischemic Stroke
The E3 ubiquitin ligase TRIM31 is involved in cerebral ischemic injury by promoting degradation of TIGAR.
Ketosis
Fructose 1,6-bisphosphatase deficiency: enzyme and mutation analysis performed on calcitriol-stimulated monocytes with a note on long-term prognosis.
Pitfall in the Diagnosis of Fructose-1,6-Bisphosphatase Deficiency: Difficulty in Detecting Glycerol-3-Phosphate with Solvent Extraction in Urinary GC/MS Analysis.
Kidney Neoplasms
Glucose metabolism involved in PD-L1-mediated immune escape in the malignant kidney tumour microenvironment.
Leukemia
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase and tumor cell glycolysis.
PFKFB4 is critical for the survival of acute monocytic leukemia cells.
Reactive Oxygen Species Drive Proliferation in Acute Myeloid Leukemia via the Glycolytic Regulator PFKFB3.
TIGAR cooperated with glycolysis to inhibit the apoptosis of leukemia cells and associated with poor prognosis in patients with cytogenetically normal acute myeloid leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Identification of TIGAR in the equilibrative nucleoside transporter 2-mediated response to fludarabine in chronic lymphocytic leukemia cells.
Leukemia, Monocytic, Acute
PFKFB4 is critical for the survival of acute monocytic leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Targeting PFKFB3 sensitizes chronic myelogenous leukemia cells to tyrosine kinase inhibitor.
Leukemia, Myeloid
Decitabine Downregulates TIGAR to Induce Apoptosis and Autophagy in Myeloid Leukemia Cells.
Leukemia, Myeloid, Acute
mTOR up-regulation of PFKFB3 is essential for acute myeloid leukemia cell survival.
Reactive Oxygen Species Drive Proliferation in Acute Myeloid Leukemia via the Glycolytic Regulator PFKFB3.
TIGAR cooperated with glycolysis to inhibit the apoptosis of leukemia cells and associated with poor prognosis in patients with cytogenetically normal acute myeloid leukemia.
Liver Cirrhosis
CPEB4 Increases Expression of PFKFB3 to Induce Glycolysis and Activate Mouse and Human Hepatic Stellate Cells, Promoting Liver Fibrosis.
Liver Neoplasms
Analysis of Key Genes Regulating the Warburg Effect in Patients with Gastrointestinal Cancers and Selective Inhibition of This Metabolic Pathway in Liver Cancer Cells.
miR-885-5p plays an accomplice role in liver cancer by instigating TIGAR expression via targeting its promoter.
PFKFB3, a key glucose metabolic enzyme regulated by pathogen recognition receptor TLR4 in liver cells.
SP1 plays a pivotal role for basal activity of TIGAR promoter in liver cancer cell lines.
Lung Neoplasms
6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene family overexpression in human lung tumor.
Cell cycle-dependent expression and subcellular localization of fructose 1,6-bisphosphatase.
Etk Interaction with PFKFB4 Modulates Chemoresistance of Small-cell Lung Cancer by Regulating Autophagy.
Fascin promotes lung cancer growth and metastasis by enhancing glycolysis and PFKFB3 expression.
Increased 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 activity in response to EGFR signaling contributes to non-small cell lung cancer cell survival.
Liposomes co-Loaded with 6-Phosphofructo-2-Kinase/Fructose-2, 6-Biphosphatase 3 (PFKFB3) shRNA Plasmid and Docetaxel for the Treatment of non-small Cell Lung Cancer.
Mechanisms of regulation of PFKFB expression in pancreatic and gastric cancer cells.
Met is involved in TIGAR-regulated metastasis of non-small-cell lung cancer.
MiR-144 Inhibits Proliferation and Induces Apoptosis and Autophagy in Lung Cancer Cells by Targeting TIGAR.
Shikonin inhibits the Warburg effect, cell proliferation, invasion and migration by downregulating PFKFB2 expression in lung cancer.
Systematic Analysis of Gene Expression Alterations and Clinical Outcomes for Long-Chain Acyl-Coenzyme A Synthetase Family in Cancer.
The Effect of TIGAR Knockdown on Apoptotic and Epithelial-Mesenchymal Markers Expression in Doxorubicin-Resistant Non-Small Cell Lung Cancer A549 Cell Lines.
TIGAR has a dual role in cancer cell survival through regulating apoptosis and autophagy.
TIGAR is correlated with maximal standardized uptake value on FDG-PET and survival in non-small cell lung cancer.
Lymphatic Metastasis
Estradiol Stimulates Glucose Metabolism via 6-Phosphofructo-2-kinase (PFKFB3).
Expression of PFKFB3 and Ki67 in lung adenocarcinomas and targeting PFKFB3 as a therapeutic strategy.
Increased expression of PFKFB3 in oral squamous cell carcinoma and its association with lymphangiogenesis.
Interleukin-6 stimulates aerobic glycolysis by regulating PFKFB3 at early stage of colorectal cancer.
PFKFB3 was overexpressed in gastric cancer patients and promoted the proliferation and migration of gastric cancer cells.
Lymphoma
Novel therapeutic interventions for p53-altered tumors through manipulation of its family members, p63 and p73.
Lymphoma, T-Cell
The TP53-Induced Glycolysis and Apoptosis Regulator mediates cooperation between HTLV-1 p30II and the retroviral oncoproteins Tax and HBZ and is highly expressed in an in vivo xenograft model of HTLV-1-induced lymphoma.
Melanoma
3PO as a Selective Inhibitor of 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3 in A375 Human Melanoma Cells.
Analysis of Malignant Melanoma Cell Lines Exposed to Hypoxia Reveals the Importance of PFKFB4 Overexpression for Disease Progression.
Expression of Alternative Splice Variants of 6-Phosphofructo-2-kinase/Fructose-2,6-bisphosphatase-4 in Normoxic and Hypoxic Melanoma Cells.
RSK Regulates PFK-2 Activity to Promote Metabolic Rewiring in Melanoma.
Splice isoform of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-4: expression and hypoxic regulation.
Mesothelioma
PFKFB3 inhibition reprograms malignant pleural mesothelioma to nutrient stress-induced macropinocytosis and ER stress as independent binary adaptive responses.
Mesothelioma, Malignant
PFKFB3 inhibition reprograms malignant pleural mesothelioma to nutrient stress-induced macropinocytosis and ER stress as independent binary adaptive responses.
Metabolic Diseases
Fetal expression of genes related to metabolic function is impacted by supplementation of ground beef and sucrose during gestation in a swine model.
Fructose 1,6- bis phosphatase: getting the message across.
Multiple Myeloma
Inhibition of the MUC1-C oncoprotein induces multiple myeloma cell death by down-regulating TIGAR expression and depleting NADPH.
KDM2A Targets PFKFB3 for Ubiquitylation to Inhibit the Proliferation and Angiogenesis of Multiple Myeloma Cells.
Targeting the MUC1-C oncoprotein is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated multiple myeloma cell death.
Multiple System Atrophy
TIGAR inclusion pathology is specific for Lewy body diseases.
Mycoses
Genetic Variation in PFKFB3 Impairs Antifungal Immunometabolic Responses and Predisposes to Invasive Pulmonary Aspergillosis.
Myocardial Infarction
p53 and TIGAR Regulate Cardiac Myocyte Energy Homeostasis Under Hypoxic Stress.
Nasopharyngeal Carcinoma
Oncogenic role of the TP53-induced glycolysis and apoptosis regulator in nasopharyngeal carcinoma through NF-?B pathway modulation.
PFKFB3 promotes proliferation, migration and angiogenesis in nasopharyngeal carcinoma.
Prognostic value of TIGAR and LC3B protein expression in nasopharyngeal carcinoma.
TP53-induced glycolysis and apoptosis regulator promotes proliferation and invasiveness of nasopharyngeal carcinoma cells.
Neoplasm Metastasis
A Potential Oncogenic Role for PFKFB3 Overexpression in Gastric Cancer Progression.
Angiogenesis revisited from a metabolic perspective: role and therapeutic implications of endothelial cell metabolism.
Blockage of glycolysis by targeting PFKFB3 suppresses tumor growth and metastasis in head and neck squamous cell carcinoma.
CircFLNA Acts as a Sponge of miR-646 to Facilitate the Proliferation, Metastasis, Glycolysis, and Apoptosis Inhibition of Gastric Cancer by Targeting PFKFB2.
Dynamic ROS Control by TIGAR Regulates the Initiation and Progression of Pancreatic Cancer.
E2F2 drives glioma progression via PI3K/AKT in a PFKFB4-dependent manner.
Endothelial cell metabolism: an update anno 2017.
Erratum: CircFLNA Acts as a Sponge of miR-646 to Facilitate the Proliferation, Metastasis, Glycolysis, and Apoptosis Inhibition of Gastric Cancer by Targeting PFKFB2 [Corrigendum].
Estradiol Stimulates Glucose Metabolism via 6-Phosphofructo-2-kinase (PFKFB3).
Expression of PFKFB3 and Ki67 in lung adenocarcinomas and targeting PFKFB3 as a therapeutic strategy.
Fascin promotes lung cancer growth and metastasis by enhancing glycolysis and PFKFB3 expression.
Higher plasma concentration of TP53-induced glycolysis and apoptosis regulator is associated with a lower risk of colorectal cancer metastasis.
Increased expression of PFKFB3 in oral squamous cell carcinoma and its association with lymphangiogenesis.
Inhibition of the Glycolytic Activator PFKFB3 in Endothelium Induces Tumor Vessel Normalization, Impairs Metastasis, and Improves Chemotherapy.
Interleukin-6 stimulates aerobic glycolysis by regulating PFKFB3 at early stage of colorectal cancer.
Met is involved in TIGAR-regulated metastasis of non-small-cell lung cancer.
PFKFB3 promotes proliferation, migration and angiogenesis in nasopharyngeal carcinoma.
PFKFB3 was overexpressed in gastric cancer patients and promoted the proliferation and migration of gastric cancer cells.
PFKFB4 Promotes Breast Cancer Metastasis via Induction of Hyaluronan Production in a p38-Dependent Manner.
ROCK2 promotes osteosarcoma growth and metastasis by modifying PFKFB3 ubiquitination and degradation.
Role of PFKFB3 and CD163 in Oral Squamous Cell Carcinoma Angiogenesis.
Role of PFKFB3 and PFKFB4 in Cancer: Genetic Basis, Impact on Disease Development/Progression, and Potential as Therapeutic Targets.
The role of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 in esophageal squamous cell carcinoma.
TIGAR promotes growth, survival and metastasis through oxidation resistance and AKT activation in glioblastoma.
Neoplasms
6-Phosphofructo-2-kinase (pfkfb3) gene promoter contains hypoxia-inducible factor-1 binding sites necessary for transactivation in response to hypoxia.
6-Phosphofructo-2-kinase (PFKFB3) promotes cell cycle progression and suppresses apoptosis via Cdk1-mediated phosphorylation of p27.
6-Phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 and 4: A pair of valves for fine-tuning of glucose metabolism in human cancer.
6-Phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 is essential for p53-null cancer cells.
6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase-2 Regulates TP53-Dependent Paclitaxel Sensitivity in Ovarian and Breast Cancers.
6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB3) is up-regulated in high-grade astrocytomas.
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase and tumor cell glycolysis.
6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene family overexpression in human lung tumor.
6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase isoform 3 spatially mediates autophagy through the AMPK signaling pathway.
A Glycolysis Outsider Steps into the Cancer Spotlight.
A High-Throughput Screening Triage Workflow to Authenticate a Novel Series of PFKFB3 Inhibitors.
A Potential Oncogenic Role for PFKFB3 Overexpression in Gastric Cancer Progression.
Aberrant methylation of human L- and M-fructose 1,6-bisphosphatase genes in cancer.
Acetylation accumulates PFKFB3 in cytoplasm to promote glycolysis and protects cells from cisplatin-induced apoptosis.
Actinomycin D and nutlin-3a synergistically promote phosphorylation of p53 on serine 46 in cancer cell lines of different origin.
Adapting glycolysis to cancer cell proliferation: the MAPK pathway focuses on PFKFB3.
Akt mediates TIGAR induction in HeLa cells following PFKFB3 inhibition.
An inducible gene product for 6-phosphofructo-2-kinase with an AU-rich instability element: role in tumor cell glycolysis and the Warburg effect.
Angiogenesis revisited from a metabolic perspective: role and therapeutic implications of endothelial cell metabolism.
Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells.
Antiproliferative cyclodepsipeptides from the marine actinomycete Streptomyces sp. P11-23B downregulating the tumor metabolic enzymes of glycolysis, glutaminolysis, and lipogenesis.
ATM-NF?B axis-driven TIGAR regulates sensitivity of glioma cells to radiomimetics in the presence of TNF?.
Autophagy in cancer associated fibroblasts promotes tumor cell survival: Role of hypoxia, HIF1 induction and NF?B activation in the tumor stromal microenvironment.
Autophagy inhibition elicits emergence from metastatic dormancy by inducing and stabilizing Pfkfb3 expression.
Balancing glycolytic flux: the role of 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatases in cancer metabolism.
Biochemical and transcript level differences between the three human phosphofructokinases show optimisation of each isoform for specific metabolic niches.
Blockage of glycolysis by targeting PFKFB3 suppresses tumor growth and metastasis in head and neck squamous cell carcinoma.
Breast Cancer Subtypes Underlying EMT-Mediated Catabolic Metabolism.
c-Src Promotes Tumorigenesis and Tumor Progression by Activating PFKFB3.
Cancer cell metabolism: there is no ROS for the weary.
CD44ICD promotes breast cancer stemness via PFKFB4-mediated glucose metabolism.
Characterization of a new liver- and kidney-specific pfkfb3 isozyme that is downregulated by cell proliferation and dedifferentiation.
Citrate targets FBPase and constitutes an emerging novel approach for cancer therapy.
Click-Nucleic-Acid-Containing Codelivery System Inducing Collapse of Cellular Homeostasis for Tumor Therapy through Bidirectional Regulation of Autophagy and Glycolysis.
Cloning and chromosomal characterization of the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 gene (PFKFB3, iPFK2).
CO-CBS-H2 S Axis: From Vascular Mediator to Cancer Regulator.
Control of Glycolytic Flux by AMP-Activated Protein Kinase in Tumor Cells Adapted to Low pH.
Crystal structure of the hypoxia-inducible form of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB3): a possible new target for cancer therapy.
Discover potential inhibitors for PFKFB3 using 3D-QSAR, virtual screening, molecular docking and molecular dynamics simulation.
Downregulation of caveolin?1 upregulates the expression of growth factors and regulators in co?culture of fibroblasts with cancer cells.
Downregulation of TIGAR sensitizes the antitumor effect of physapubenolide through increasing intracellular ROS levels to trigger apoptosis and autophagosome formation in human breast carcinoma cells.
Dual inhibition of PFKFB3 and VEGF normalizes tumor vasculature, reduces lactate production, and improves chemotherapy in glioblastoma: insights from protein expression profiling and MRI.
Dynamic ROS Control by TIGAR Regulates the Initiation and Progression of Pancreatic Cancer.
Dynamic ROS Regulation by TIGAR: Balancing Anti-cancer and Pro-metastasis Effects.
E2F2 drives glioma progression via PI3K/AKT in a PFKFB4-dependent manner.
Effects of the Novel PFKFB3 Inhibitor KAN0438757 on Colorectal Cancer Cells and Its Systemic Toxicity Evaluation In Vivo.
Endothelial cell metabolism: an update anno 2017.
Expression and hypoxia-responsiveness of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 in mammary gland malignant cell lines.
Expression of 6-phosphofructo-2-kinase/ fructose-2,6-bisphosphatase-3 and VEGF mRNA in rat liver, lung and heart: effect of methyl tertbutyl ether.
Expression of PFKFB3 and Ki67 in lung adenocarcinomas and targeting PFKFB3 as a therapeutic strategy.
Expression of TIGAR and its correlation with clinicopathology, prognosis, and 18F-FDG PET/CT parameters in patients with resectable pancreatic ductal adenocarcinoma.
Finding clues in the p53 maze: an interview with Karen Vousden.
Fructose 1,6- bis phosphatase: getting the message across.
Fructose 2,6-Bisphosphate in Cancer Cell Metabolism.
Fructose 2,6-bisphosphate metabolism in Ehrlich ascites tumour cells.
Fructose-2,6-bisphosphate synthesis by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 (PFKFB4) is required for the glycolytic response to hypoxia and tumor growth.
Functional diversity of PFKFB3 splice variants in glioblastomas.
Functional metabolic screen identifies 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 as an important regulator of prostate cancer cell survival.
Genetic alteration in phosphofructokinase family promotes growth of muscle-invasive bladder cancer.
Genome-scale CRISPR knockout screen identifies TIGAR as a modifier of PARP inhibitor sensitivity.
Gluconeogenesis in Cancer: Function and Regulation of PEPCK, FBPase, and G6Pase.
Glucose deprivation increases mRNA stability of vascular endothelial growth factor through activation of AMP-activated protein kinase in DU145 prostate carcinoma.
Glycolysis links p53 function with NF-kappaB signaling: impact on cancer and aging process.
Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma.
HIF-1? activates hypoxia-induced PFKFB4 expression in human bladder cancer cells.
High expression of inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (iPFK-2; PFKFB3) in human cancers.
High expression of metabolic enzyme PFKFB4 is associated with poor prognosis of operable breast cancer.
Higher plasma concentration of TP53-induced glycolysis and apoptosis regulator is associated with a lower risk of colorectal cancer metastasis.
Hypoxia induces transcription of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase-4 gene via hypoxia-inducible factor-1alpha activation.
Hypoxia, glucose metabolism and the Warburg's effect.
Hypoxic regulation of PFKFB-3 and PFKFB-4 gene expression in gastric and pancreatic cancer cell lines and expression of PFKFB genes in gastric cancers.
Identification and characterization of the hypoxia-responsive element of the human placental 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene.
Identification of the TP53-induced glycolysis and apoptosis regulator in various stages of colorectal cancer patients.
Identification of TP53-induced glycolysis and apoptosis regulator (TIGAR) as the phosphoglycolate-independent 2,3-bisphosphoglycerate phosphatase.
In silico identification of potential inhibitor for TP53-induced glycolysis and apoptosis regulator in head and neck squamous cell carcinoma.
In vitro angiogenesis inhibition with selective compounds targeting the key glycolytic enzyme PFKFB3.
Inhibition of 6-phosphofructo-2-kinase (PFKFB3) induces autophagy as a survival mechanism.
Inhibition of c-Met downregulates TIGAR expression and reduces NADPH production leading to cell death.
Inhibition of Glycolysis Suppresses Cell Proliferation and Tumor Progression In Vivo: Perspectives for Chronotherapy.
Inhibition of glycolytic activator PFKFB3 suppresses tumor growth and induces tumor vessel normalization in hepatocellular carcinoma.
Inhibition of Growth by Combined Treatment with Inhibitors of Lactate Dehydrogenase and either Phenformin or Inhibitors of 6-Phosphofructo-2-kinase/Fructose-2,6-bisphosphatase 3.
Inhibition of PFKFB3 induces cell death and synergistically enhances chemosensitivity in endometrial cancer.
Inhibition of the Glycolytic Activator PFKFB3 in Endothelium Induces Tumor Vessel Normalization, Impairs Metastasis, and Improves Chemotherapy.
Interleukin-6 stimulates aerobic glycolysis by regulating PFKFB3 at early stage of colorectal cancer.
INTRACELLULAR TARGETING OF THE ONCOGENIC MUC1-C PROTEIN WITH A NOVEL GO-203 NANOPARTICLE FORMULATION.
Investigating combinatorial approaches in virtual screening on human inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB3): A case study for small molecule kinases.
KDM2A Targets PFKFB3 for Ubiquitylation to Inhibit the Proliferation and Angiogenesis of Multiple Myeloma Cells.
Kinome Screen Identifies PFKFB3 and Glucose Metabolism as Important Regulators of the Insulin/Insulin-like Growth Factor (IGF)-1 Signaling Pathway.
Knockdown of the TP53-Induced Glycolysis and Apoptosis Regulator (TIGAR) Sensitizes Glioma Cells to Hypoxia, Irradiation and Temozolomide.
LOH on 10p14-p15 targets the PFKFB3 gene locus in human glioblastomas.
Long noncoding RNA AGPG regulates PFKFB3-mediated tumor glycolytic reprogramming.
Long noncoding RNA FIRRE contributes to the proliferation and glycolysis of hepatocellular carcinoma cells by enhancing PFKFB4 expression.
Lymphotoxin-? promotes tumor angiogenesis in HNSCC by modulating glycolysis in a PFKFB3 dependent manner.
Mechanisms of regulation of PFKFB expression in pancreatic and gastric cancer cells.
Met is involved in TIGAR-regulated metastasis of non-small-cell lung cancer.
Metabolic remodeling by TIGAR overexpression is a therapeutic target in esophageal squamous-cell carcinoma.
microRNA-144 inhibits cell proliferation and invasion by directly targeting TIGAR in esophageal carcinoma.
MicroRNA-26b inhibits osteosarcoma cell migration and invasion by down-regulating PFKFB3 expression.
MicroRNA-3666 Suppresses Cell Growth in Head and Neck Squamous Cell Carcinoma Through Inhibition of PFKFB3-Mediated Warburg Effect.
miR-1297 Suppresses Osteosarcoma Proliferation and Aerobic Glycolysis by Regulating PFKFB2.
miR-139-5p inhibits aerobic glycolysis, cell proliferation, migration, and invasion in hepatocellular carcinoma via a reciprocal regulatory interaction with ETS1.
miR-613 inhibits Warburg effect in gastric cancer by targeting PFKFB2.
Monocyte fructose 1,6-bisphosphatase and cytidine deaminase enzyme activities: potential pharmacodynamic measures of calcitriol effects in cancer patients.
Necroptosis pathway blockage attenuates PFKFB3 inhibitor-induced cell viability loss and genome instability in colorectal cancer cells.
Novel therapeutic interventions for p53-altered tumors through manipulation of its family members, p63 and p73.
Nuclear targeting of 6-phosphofructo-2-kinase (PFKFB3) increases proliferation via cyclin-dependent kinases.
O-GlcNAcylation of PFKFB3 is required for tumor cell proliferation under hypoxia.
Oncogenic role of the TP53-induced glycolysis and apoptosis regulator in nasopharyngeal carcinoma through NF-?B pathway modulation.
Overexpression of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-4 in the human breast and colon malignant tumors.
Overexpression of ubiquitous 6-phosphofructo-2-kinase in the liver of transgenic mice results in weight gain.
p53 coordinates DNA repair with nucleotide synthesis by suppressing PFKFB3 expression and promoting the pentose phosphate pathway.
p53- and p73-independent activation of TIGAR expression in vivo.
PELP1/SRC-3-dependent regulation of metabolic PFKFB kinases drives therapy resistant ER+ breast cancer.
PFK15, a Small Molecule Inhibitor of PFKFB3, Induces Cell Cycle Arrest, Apoptosis and Inhibits Invasion in Gastric Cancer.
Pfkfb (6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase) isoforms display a tissue-specific and dynamic expression during Xenopus laevis development.
PFKFB2 regulates glycolysis and proliferation in pancreatic cancer cells.
PFKFB3 activation in cancer cells by the p38/MK2 pathway in response to stress stimuli.
PFKFB3 blockade inhibits hepatocellular carcinoma growth by impairing DNA repair through AKT.
PFKFB3 Control of Cancer Growth by Responding to Circadian Clock Outputs.
PFKFB3 Inhibition Attenuates Oxaliplatin-Induced Autophagy and Enhances Its Cytotoxicity in Colon Cancer Cells.
PFKFB3 Inhibition Sensitizes DNA Crosslinking Chemotherapies by Suppressing Fanconi Anemia Repair.
PFKFB3 inhibitors as potential anticancer agents: Mechanisms of action, current developments, and structure-activity relationships.
PFKFB3 is involved in breast cancer proliferation, migration, invasion and angiogenesis.
PFKFB3 modulates glycolytic metabolism and alleviates endoplasmic reticulum stress in human osteoarthritis cartilage.
PFKFB3 promotes proliferation, migration and angiogenesis in nasopharyngeal carcinoma.
PFKFB3 regulates oxidative stress homeostasis via its S-glutathionylation in cancer.
PFKFB4 as a prognostic marker in non-muscle-invasive bladder cancer.
PFKFB4 as a promising biomarker to predict a poor prognosis in patients with gastric cancer.
PFKFB4 negatively regulated the expression of histone acetyltransferase GCN5 to mediate the tumorigenesis of thyroid cancer.
PFKFB4 Overexpression Facilitates Proliferation by Promoting the G1/S Transition and Is Associated with a Poor Prognosis in Triple-Negative Breast Cancer.
PFKFB4 Promotes Breast Cancer Metastasis via Induction of Hyaluronan Production in a p38-Dependent Manner.
Phosphoproteomic Analysis of X enopus laevis Reveals Expression and Phosphorylation of Hypoxia-Inducible PFKFB3 during Dehydration.
Phosphorylation of the 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase/PFKFB3 family of glycolytic regulators in human cancer.
Positive regulation of PFKFB3 by PIM2 promotes glycolysis and paclitaxel resistance in breast cancer.
Prognostic Value of PFKFB3 to PFKFB4 mRNA Ratio in Patients With Primary Glioblastoma (IDH-Wildtype).
Prognostic Values of TIGAR Expression and 18F-FDG PET/CT in Clear Cell Renal Cell Carcinoma.
Ras transformation requires metabolic control by 6-phosphofructo-2-kinase.
Reactive Oxygen Species-Dependent Down-Regulation of Tumor Suppressor Genes PTEN, USP28, DRAM, TIGAR, and CYLD Under Oxidative Stress.
Reduced methylation of PFKFB3 in cancer cells shunts glucose towards the pentose phosphate pathway.
Regulation of glucose metabolism by p53: emerging new roles for the tumor suppressor.
Regulatory role of p53 in cancer metabolism via SCO2 and TIGAR in human breast cancer.
Relocation of phosphofructokinases within epithelial cells is a novel event preceding breast cancer recurrence that accurately predicts patient outcomes.
Resveratrol inhibits TIGAR to promote ROS induced apoptosis and autophagy.
RNAi screening in glioma stem-like cells identifies PFKFB4 as a key molecule important for cancer cell survival.
Role of PFKFB3 and CD163 in Oral Squamous Cell Carcinoma Angiogenesis.
Role of PFKFB3 and PFKFB4 in Cancer: Genetic Basis, Impact on Disease Development/Progression, and Potential as Therapeutic Targets.
Roles of PFKFB3 in cancer.
SCO2 Induces p53-Mediated Apoptosis by Thr845 Phosphorylation of ASK-1 and Dissociation of the ASK-1-Trx Complex.
Structure, regulation, and biological functions of TIGAR and its role in diseases.
Structure-based development of small molecule PFKFB3 inhibitors: a framework for potential cancer therapeutic agents targeting the Warburg effect.
Studying Antitumor Effects of Sirna Gene Silencing of some Metabolic Genes in Pancreatic Ductal Adenocarcinoma.
Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer.
Targeting FBPase is an emerging novel approach for cancer therapy.
Targeting of MCT1 and PFKFB3 influences cell proliferation and apoptosis in bladder cancer by altering the tumor microenvironment.
Targeting PFKFB3 in the Endothelium for Cancer Therapy.
Targeting PFKFB3 radiosensitizes cancer cells and suppresses homologous recombination.
Targeting the sugar metabolism of tumors with a first-in-class 6-phosphofructo-2-kinase (PFKFB4) inhibitor.
Targeting the Warburg Effect in cancer; relationships for 2-arylpyridazinones as inhibitors of the key glycolytic enzyme 6-phosphofructo-2-kinase/2,6-bisphosphatase 3 (PFKFB3).
The diverse role of TIGAR in cellular homeostasis and cancer.
The expression pattern of PFKFB3 enzyme distinguishes between induced-pluripotent stem cells and cancer stem cells.
The Glycolytic Enzyme PFKFB3 Controls TNF-?-Induced Endothelial Proinflammatory Responses.
The influence of PFK-II overexpression on neuroblastoma patients' survival may be dependent on the particular isoenzyme expressed, PFKFB3 or PFKFB4.
The JAK2V617F oncogene requires expression of inducible phosphofructokinase/fructose-bisphosphatase 3 for cell growth and increased metabolic activity.
The molecular basis of targeting PFKFB3 as a therapeutic strategy against cancer.
The PFKFB3 splice variant UBI2K4 is down-regulated in high-grade astrocytomas and impedes the growth of U87 glioblastoma cells.
The potential utility of PFKFB3 as a therapeutic target.
The role of 6-phosphofructo-2-kinase (PFK-2)/fructose 2,6-bisphosphatase (FBPase-2) in metabolic reprogramming of cancer cells.
The role of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 in esophageal squamous cell carcinoma.
The TP53-Induced Glycolysis and Apoptosis Regulator mediates cooperation between HTLV-1 p30II and the retroviral oncoproteins Tax and HBZ and is highly expressed in an in vivo xenograft model of HTLV-1-induced lymphoma.
Therapeutic targeting of PFKFB3 with a novel glycolytic inhibitor PFK158 promotes lipophagy and chemosensitivity in gynecologic cancers.
Therapeutic Targeting of the Warburg Effect in Pancreatic Cancer Relies on an Absence of p53 Function.
TIGAR has a dual role in cancer cell survival through regulating apoptosis and autophagy.
TIGAR induces p53-mediated cell-cycle arrest by regulation of RB-E2F1 complex.
TIGAR inhibits ischemia/reperfusion-induced inflammatory response of astrocytes.
TIGAR is correlated with maximal standardized uptake value on FDG-PET and survival in non-small cell lung cancer.
TIGAR is required for efficient intestinal regeneration and tumorigenesis.
TIGAR knockdown enhanced the anticancer effect of aescin via regulating autophagy and apoptosis in colorectal cancer cells.
TIGAR knockdown radiosensitizes TrxR1-overexpressing glioma in vitro and in vivo via inhibiting Trx1 nuclear transport.
TIGAR Promotes Tumorigenesis and Protects Tumor Cells From Oxidative and Metabolic Stresses in Gastric Cancer.
TIGAR regulates DNA damage and repair through pentosephosphate pathway and Cdk5-ATM pathway.
TIGAR's promiscuity.
TIGAR, TIGAR, burning bright.
To PFKFB3 or Not to PFKFB3, That Is the Question.
TP53 induced glycolysis and apoptosis regulator (TIGAR) knockdown results in radiosensitization of glioma cells.
TP53-inducible Glycolysis and Apoptosis Regulator (TIGAR) Metabolically Reprograms Carcinoma and Stromal Cells in Breast Cancer.
Tristetraprolin posttranscriptionally downregulates PFKFB3 in cancer cells.
Tumor vessel disintegration by maximum tolerable PFKFB3 blockade.
Ubiquitin-like protein FAT10 promotes osteosarcoma glycolysis and growth by upregulating PFKFB3 via stabilization of EGFR.
Upregulation of 6-phosphofructo-2-kinase (PFKFB3) by hyperactivated mammalian target of rapamycin complex 1 is critical for tumor growth in tuberous sclerosis complex.
[Antineoplastic properties of extracellular fructoso-1,6-bisphosphatase of Bacillus subtilis 668 and preparation isolated from cultural liquids of Bacillus subtilis 7025]
[EXPRESSION OF PFKFB, HK2, NAMPT, TSPAN13 AND HSPB8 GENES IN PEDIATRIC GLIOMA].
Neoplastic Cells, Circulating
PELP1/SRC-3-dependent regulation of metabolic PFKFB kinases drives therapy resistant ER+ breast cancer.
Neuroblastoma
The influence of PFK-II overexpression on neuroblastoma patients' survival may be dependent on the particular isoenzyme expressed, PFKFB3 or PFKFB4.
Neurodegenerative Diseases
TIGAR inclusion pathology is specific for Lewy body diseases.
Neuroinflammatory Diseases
Targeting neuroinflammation to treat cerebral ischemia - The role of TIGAR/NADPH axis.
Non-alcoholic Fatty Liver Disease
Indole Alleviates Diet-induced Hepatic Steatosis and Inflammation in a Manner Involving Myeloid Cell PFKFB3.
Obesity
Adipose tissue inflammation and systemic insulin resistance in mice with diet-induced obesity is possibly associated with disruption of PFKFB3 in hematopoietic cells.
Association analysis of positional obesity candidate genes based on integrated data from transcriptomics and linkage analysis.
[EXPRESSION OF GENES, WHICH CONTROL GLUCOSE METABOLISM, IN BLOOD CELLS OF THE OBESE BOYS WITH INSULIN RESISTANCE].
Obesity, Maternal
Loss of TIGAR Induces Oxidative Stress and Meiotic Defects in Oocytes from Obese Mice.
Obesity, Morbid
Association analysis of positional obesity candidate genes based on integrated data from transcriptomics and linkage analysis.
Osteoarthritis
Inhibition of 6-phosphofructo-2-kinase suppresses fibroblast-like synoviocytes-mediated synovial inflammation and joint destruction in rheumatoid arthritis.
PFKFB3 modulates glycolytic metabolism and alleviates endoplasmic reticulum stress in human osteoarthritis cartilage.
Osteosarcoma
MicroRNA-26b inhibits osteosarcoma cell migration and invasion by down-regulating PFKFB3 expression.
miR-1297 Suppresses Osteosarcoma Proliferation and Aerobic Glycolysis by Regulating PFKFB2.
miR-26b inhibits proliferation, migration, invasion and apoptosis induction via the downregulation of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 driven glycolysis in osteosarcoma cells.
ROCK2 promotes osteosarcoma growth and metastasis by modifying PFKFB3 ubiquitination and degradation.
Ubiquitin-like protein FAT10 promotes osteosarcoma glycolysis and growth by upregulating PFKFB3 via stabilization of EGFR.
Ovarian Neoplasms
A comparative analysis of inhibitors of the glycolysis pathway in breast and ovarian cancer cell line models.
Expression of glycolytic enzymes in ovarian cancers and evaluation of the glycolytic pathway as a strategy for ovarian cancer treatment.
Genome-scale CRISPR knockout screen identifies TIGAR as a modifier of PARP inhibitor sensitivity.
Loss of PFKFB4 induces cell death in mitotically arrested ovarian cancer cells.
Pancreatic Neoplasms
Dynamic ROS Control by TIGAR Regulates the Initiation and Progression of Pancreatic Cancer.
Hypoxic regulation of PFKFB-3 and PFKFB-4 gene expression in gastric and pancreatic cancer cell lines and expression of PFKFB genes in gastric cancers.
Low glucose enhanced metformin's inhibitory effect on pancreatic cancer cells by suppressing glycolysis and inducing energy stress via up-regulation of miR-210-5p.
Mechanisms of regulation of PFKFB expression in pancreatic and gastric cancer cells.
PFKFB2 regulates glycolysis and proliferation in pancreatic cancer cells.
Studying Antitumor Effects of Sirna Gene Silencing of some Metabolic Genes in Pancreatic Ductal Adenocarcinoma.
Parkinson Disease
TIGAR inclusion pathology is specific for Lewy body diseases.
Pneumonia
Pathogenetic profiling of COVID-19 and SARS-like viruses.
Pre-Eclampsia
Increased expression and phosphorylation of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase isoforms in urinary exosomes in pre-eclampsia.
MALAT1 sponges miR-26a and miR-26b to regulate endothelial cell angiogenesis via PFKFB3-driven glycolysis in early-onset preeclampsia.
PFKFB3 regulates lipopolysaccharide-induced excessive inflammation and cellular dysfunction in HTR-8/Svneo cells: Implications for the role of PFKFB3 in preeclampsia.
Prostatic Hyperplasia
The metabolic role of PFKFB4 in androgen-independent growth in vitro and PFKFB4 expression in human prostate cancer tissue.
Prostatic Neoplasms
Androgen stimulates glycolysis for de novo lipid synthesis by increasing the activities of hexokinase 2 and 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2 in prostate cancer cells.
CD44 regulates prostate cancer proliferation, invasion and migration via PDK1 and PFKFB4.
Functional metabolic screen identifies 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 as an important regulator of prostate cancer cell survival.
Hypoxia induces transcription of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase-4 gene via hypoxia-inducible factor-1alpha activation.
Identification of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase as a novel autophagy regulator by high content shRNA screening.
MicroRNA-488 inhibits proliferation and glycolysis in human prostate cancer cells by regulating PFKFB3.
miR-101 Enhances Cisplatin-Induced DNA Damage Through Decreasing Nicotinamide Adenine Dinucleotide Phosphate Levels by Directly Repressing Tp53-Induced Glycolysis and Apoptosis Regulator Expression in Prostate Cancer Cells.
The metabolic role of PFKFB4 in androgen-independent growth in vitro and PFKFB4 expression in human prostate cancer tissue.
Pulmonary Arterial Hypertension
Involvement of PFKFB3 in Pulmonary Arterial Hypertension Pathogenesis. Is It All about Glycolysis?
PFKFB3 in Smooth Muscle Promotes Vascular Remodeling in Pulmonary Arterial Hypertension.
Pulmonary Edema
Ablation of endothelial Pfkfb3 protects mice from acute lung injury in LPS-induced endotoxemia.
Pulmonary Fibrosis
PI3K-Akt-mTOR/PFKFB3 pathway mediated lung fibroblast aerobic glycolysis and collagen synthesis in lipopolysaccharide-induced pulmonary fibrosis.
Reperfusion Injury
Effect of microRNA-26a on vascular endothelial cell injury caused by lower extremity ischemia-reperfusion injury through the AMPK pathway by targeting PFKFB3.
Metformin regulates the Th17/Treg balance by glycolysis with TIGAR in hepatic ischemia-reperfusion injury.
Targeting PFKFB3 alleviates cerebral ischemia-reperfusion injury in mice.
TIGAR contributes to ischemic tolerance induced by cerebral preconditioning through scavenging of reactive oxygen species and inhibition of apoptosis.
TIGAR regulates glycolysis in ischemic kidney proximal tubules.
Respiratory Syncytial Virus Infections
PFKFB3-Driven Macrophage Glycolytic Metabolism Is a Crucial Component of Innate Antiviral Defense.
Retinoblastoma
Structure, regulation, and biological functions of TIGAR and its role in diseases.
TIGAR induces p53-mediated cell-cycle arrest by regulation of RB-E2F1 complex.
Rhabdomyosarcoma
PFK15, a PFKFB3 antagonist, inhibits autophagy and proliferation in rhabdomyosarcoma cells.
Sarcoidosis
Novel protein pathways in development and progression of pulmonary sarcoidosis.
Sarcoma 37
[Antineoplastic properties of extracellular fructoso-1,6-bisphosphatase of Bacillus subtilis 668 and preparation isolated from cultural liquids of Bacillus subtilis 7025]
Sarcoma, Avian
Activation of 6-phosphofructo-2-kinase by pp60v-src is an indirect effect.
Seizures
TIGAR suppresses seizures induced by kainic acid through inhibiting oxidative stress and neuronal apoptosis.
Sepsis
Correction: Zhx2 Accelerates Sepsis by Promoting Macrophage Glycolysis via Pfkfb3.
Identification of Potential Transcriptional Biomarkers Differently Expressed in Both S. aureus- and E. coli-Induced Sepsis via Integrated Analysis.
Zhx2 Accelerates Sepsis by Promoting Macrophage Glycolysis via Pfkfb3.
Severe Acute Respiratory Syndrome
Pathogenetic profiling of COVID-19 and SARS-like viruses.
Spinal Cord Injuries
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase Suppresses Neuronal Apoptosis by Increasing Glycolysis and "cyclin-dependent kinase 1-Mediated Phosphorylation of p27 After Traumatic Spinal Cord Injury in Rats.
Squamous Cell Carcinoma of Head and Neck
Blockage of glycolysis by targeting PFKFB3 suppresses tumor growth and metastasis in head and neck squamous cell carcinoma.
In silico identification of potential inhibitor for TP53-induced glycolysis and apoptosis regulator in head and neck squamous cell carcinoma.
Increased expression of PFKFB3 in oral squamous cell carcinoma and its association with lymphangiogenesis.
Lymphotoxin-? promotes tumor angiogenesis in HNSCC by modulating glycolysis in a PFKFB3 dependent manner.
MicroRNA-3666 Suppresses Cell Growth in Head and Neck Squamous Cell Carcinoma Through Inhibition of PFKFB3-Mediated Warburg Effect.
Role of PFKFB3 and CD163 in Oral Squamous Cell Carcinoma Angiogenesis.
Starvation
Age-dependent glycolysis and gluconeogenesis enzyme activities in starved-refed rats.
Changes in rat hepatic fructose 2,6-bisphosphate and 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase activity during three days of consumption of a high protein diet or starvation.
Comparison between starvation and consumption of a high protein diet: plasma insulin and glucagon and hepatic activities of gluconeogenic enzymes during the first 24 hours.
Degradation of the gluconeogenic enzymes fructose-1,6-bisphosphatase and malate dehydrogenase is mediated by distinct proteolytic pathways and signaling events.
Effect of starvation on gene expression of regulatory enzymes of glycolysis/gluconeogenesis in genetically obese (fa/fa) Zucker rats.
Induction of rat liver 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase mRNA by refeeding and insulin.
Inhibition of 6-phosphofructo-2-kinase (PFKFB3) induces autophagy as a survival mechanism.
KRAB-type zinc-finger proteins PITA and PISA specifically regulate p53-dependent glycolysis and mitochondrial respiration.
Modulation of intracellular ROS levels by TIGAR controls autophagy.
Predominant periportal expression of the fructose 1,6-bisphosphatase gene in rat liver: dynamics during the daily feeding rhythm and starvation-refeeding cycle.
The TOR complex 1 is distributed in endosomes and in retrograde vesicles that form from the vacuole membrane and plays an important role in the vacuole import and degradation pathway.
Tp53-induced glycolysis and apoptosis regulator (TIGAR) protects glioma cells from starvation-induced cell death by upregulating respiration and improving cellular redox homeostasis.
Vps34p is required for the decline of extracellular fructose-1,6-bisphosphtase in the vacuole import and degradation pathway.
Stomach Neoplasms
A Potential Oncogenic Role for PFKFB3 Overexpression in Gastric Cancer Progression.
CircFLNA Acts as a Sponge of miR-646 to Facilitate the Proliferation, Metastasis, Glycolysis, and Apoptosis Inhibition of Gastric Cancer by Targeting PFKFB2.
Distinctive interrelation of p53 with SCO2, COX, and TIGAR in human gastric cancer.
Erratum: CircFLNA Acts as a Sponge of miR-646 to Facilitate the Proliferation, Metastasis, Glycolysis, and Apoptosis Inhibition of Gastric Cancer by Targeting PFKFB2 [Corrigendum].
Hypoxic regulation of PFKFB-3 and PFKFB-4 gene expression in gastric and pancreatic cancer cell lines and expression of PFKFB genes in gastric cancers.
Long non-coding RNA MSC-AS1 facilitates the proliferation and glycolysis of gastric cancer cells by regulating PFKFB3 expression.
Mechanisms of regulation of PFKFB expression in pancreatic and gastric cancer cells.
miR-449c inhibits migration and invasion of gastric cancer cells by targeting PFKFB3.
miR-613 inhibits Warburg effect in gastric cancer by targeting PFKFB2.
PFK15, a Small Molecule Inhibitor of PFKFB3, Induces Cell Cycle Arrest, Apoptosis and Inhibits Invasion in Gastric Cancer.
PFKFB3 was overexpressed in gastric cancer patients and promoted the proliferation and migration of gastric cancer cells.
PFKFB4 as a promising biomarker to predict a poor prognosis in patients with gastric cancer.
Protein kinase D3 promotes gastric cancer development through p65/6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 activation of glycolysis.
Rev-erb? inhibits proliferation by reducing glycolytic flux and pentose phosphate pathway in human gastric cancer cells.
TIGAR Promotes Tumorigenesis and Protects Tumor Cells From Oxidative and Metabolic Stresses in Gastric Cancer.
Stroke
A TIGAR-regulated metabolic pathway is critical for protection of brain ischemia.
Ischemia/reperfusion-induced upregulation of TIGAR in brain is mediated by SP1 and modulated by ROS and hormones involved in glucose metabolism.
Targeting PFKFB3 alleviates cerebral ischemia-reperfusion injury in mice.
TIGAR alleviates ischemia/reperfusion-induced autophagy and ischemic brain injury.
TIGAR inhibits ischemia/reperfusion-induced inflammatory response of astrocytes.
Thrombosis
Prognostic Values of TIGAR Expression and 18F-FDG PET/CT in Clear Cell Renal Cell Carcinoma.
Thyroid Neoplasms
PFKFB2 Promoter Hypomethylation as Recurrence Predictive Marker in Well-Differentiated Thyroid Carcinomas.
PFKFB4 negatively regulated the expression of histone acetyltransferase GCN5 to mediate the tumorigenesis of thyroid cancer.
Tongue Neoplasms
PFKFB3 Control of Cancer Growth by Responding to Circadian Clock Outputs.
Triple Negative Breast Neoplasms
6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase-2 Regulates TP53-Dependent Paclitaxel Sensitivity in Ovarian and Breast Cancers.
PFKFB4 Overexpression Facilitates Proliferation by Promoting the G1/S Transition and Is Associated with a Poor Prognosis in Triple-Negative Breast Cancer.
Tuberculosis
The Mycobacterium tuberculosis Rv1099c gene encodes a GlpX-like class II fructose 1,6-bisphosphatase.
Urinary Bladder Neoplasms
A glycolysis-based 4-mRNA signature correlates with the prognosis and cell cycle process in patients with bladder cancer.
Genetic alteration in phosphofructokinase family promotes growth of muscle-invasive bladder cancer.
HIF-1? activates hypoxia-induced PFKFB4 expression in human bladder cancer cells.
PFKFB4 as a prognostic marker in non-muscle-invasive bladder cancer.
Targeting of MCT1 and PFKFB3 influences cell proliferation and apoptosis in bladder cancer by altering the tumor microenvironment.
Uterine Cervical Neoplasms
Carbonic Anhydrase IX Promotes Human Cervical Cancer Cell Motility by Regulating PFKFB4 Expression.
Vascular Calcification
?-opioid receptor stimulation alleviates rat vascular smooth muscle cell calcification via PFKFB3-lactate signaling.
Virus Diseases
PFKFB3-Driven Macrophage Glycolytic Metabolism Is a Crucial Component of Innate Antiviral Defense.
Vitamin A Deficiency
Vitamin A regulates genes involved in hepatic gluconeogenesis in mice: phosphoenolpyruvate carboxykinase, fructose-1,6-bisphosphatase and 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase.